U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: An analysis of medicare, medicaid, and commercial insurance

This is the authors' abstract. We don't add key points for this paper.

Aflibercept 2 mg was the most common drug used overall from 2017-2023. Faricimab had the highest absolute and relative increase in utilization from 2022-2023. Patients with Medicare B or C were significantly more likely to receive aflibercept over bevacizumab.